Cyclosporine Market Report 2025

The cyclosporine market size has grown rapidly in recent years. It will grow from $2.65 billion in 2024 to $2.98 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to the rising number of organ transplants, increasing autoimmune cases, growing chronic diseases, surging kidney disorders, and expansion of transplant centers.

The cyclosporine market size is expected to see rapid growth in the next few years. It will grow to $4.85 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to rising organ donations, expanding immunotherapy adoption, a rising geriatric patient pool, an expanding specialty pharmaceutical market, and a rising incidence of rheumatoid arthritis. Major trends in the forecast period include the development of novel immunosuppressive therapies, innovation in AI-driven drug development, development in nanotechnology integration, innovation in blockchain in drug supply chain, and advancements in drug delivery.

The forecast of 12.9% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. transplant centers by inflating prices of cyclosporine immunosuppressants sourced from Israel and India, resulting in compromised organ rejection prevention and higher post-transplantation care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of autoimmune diseases is expected to significantly drive growth in the cyclosporine market. Autoimmune diseases are characterized by the immune system mistakenly attacking the body’s own tissues, resulting in inflammation, organ damage, and chronic conditions. Contributing factors include genetic predisposition and advancements in genetic diagnostics, which have led to better identification of individuals at higher risk. Cyclosporine, a potent immunosuppressant, is widely used to treat autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis by inhibiting T-cell activation and moderating excessive immune responses. For example, in May 2024, the National Institutes of Health (NIH) reported that the prevalence of psoriatic arthritis (PsA) in 2022 was 0.221%, with an incidence rate of 13.54 per 100,000 individuals. These rising disease rates are generating increased demand for cyclosporine, underscoring its vital role in autoimmune disease management.

Companies within the cyclosporine market are increasingly focused on achieving regulatory approvals to enhance product credibility and market reach. Regulatory endorsement affirms a product’s safety and therapeutic efficacy, enabling broader adoption and strengthening stakeholder confidence. For instance, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical firm, received U.S. FDA approval for VEVYE (cyclosporine ophthalmic solution) 0.1%. This product is the first water-free cyclosporine solution approved for the treatment of dry eye disease (DED), demonstrating effectiveness within four weeks of use. VEVYE leverages EyeSol technology, a novel water-free formulation that enhances bioavailability and ocular surface retention without using preservatives, oils, or surfactants. As a calcineurin inhibitor, it reduces inflammation associated with DED, offering a differentiated treatment option in the ophthalmic segment.

In July 2024, Lupin Limited, an India-based pharmaceutical company, announced a strategic partnership with Huons Co. Ltd. to launch a cyclosporine ophthalmic nanoemulsion in Mexico. The collaboration aims to commercialize this advanced formulation for treating dry eye syndrome and ocular inflammation, thereby expanding Lupin’s ophthalmic product offerings and reinforcing its presence in Latin America. Huons Co. Ltd., a South Korea-based pharmaceutical innovator, specializes in developing and commercializing ophthalmic therapies, including advanced cyclosporine-based formulations. This partnership reflects ongoing efforts in the industry to address unmet needs in eye care through cross-border collaboration and innovation.

Major players in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, and Logos Pharma.

Asia-Pacific was the largest region in the cyclosporine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in cyclosporine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cyclosporine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cyclosporine market consists of sales of injectable cyclosporine, ophthalmic formulations, intravenous solutions, topical formulations, and oral solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The cyclosporine market research report is one of a series of new reports that provides cyclosporine market statistics, including cyclosporine industry global market size, regional shares, competitors with a cyclosporine market share, detailed cyclosporine market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine industry. This cyclosporine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cyclosporine is an immunosuppressive drug mainly used to prevent organ transplant rejection and to manage specific autoimmune diseases. It functions by inhibiting T-cell activity through suppression of the enzyme calcineurin, effectively reducing inflammation and immune system responses. Additionally, cyclosporine is utilized in ophthalmic formulations to treat eye conditions such as dry eye disease.

The primary indications for cyclosporine include transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, autoimmune myasthenia gravis, dry eye, and others. Transplant rejection prophylaxis refers to the use of cyclosporine in preventing the immune system from rejecting transplanted organs, such as the kidney, liver, or heart. Cyclosporine is available in several dosage forms, including capsules, eye drops, liquid solutions, creams, and ointments, and is administered through oral, topical, and parenteral routes. It is distributed via hospital pharmacies, retail pharmacies, and online pharmacies and is used by various end users, including hospitals, homecare settings, specialty centers, and others.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.